Direkt zum Inhalt
  1. Publizieren |
  2. Suche |
  3. Browsen |
  4. Neuzugänge rss |
  5. Open Access |
  6. Rechtsfragen |
  7. EnglishCookie löschen - von nun an wird die Spracheinstellung Ihres Browsers verwendet.

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

Haense, N. ; Atmaca, A. ; Pauligk, C. ; Steinmetz, K. ; Marmé, Frederik ; Haag, Georg-Martin ; Rieger, M. ; Ottmann, O. G. ; Ruf, P. ; Lindhofer, H. ; Al-Batran, S.-E.

In: BMC Cancer, 16 (2016), Nr. 420. S. 1-10. ISSN 1471-2407

[thumbnail of 12885_2016_Article_2449.pdf]
Vorschau
PDF, Englisch
Download (990kB) | Lizenz: Creative Commons LizenzvertragA phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors von Haense, N. ; Atmaca, A. ; Pauligk, C. ; Steinmetz, K. ; Marmé, Frederik ; Haag, Georg-Martin ; Rieger, M. ; Ottmann, O. G. ; Ruf, P. ; Lindhofer, H. ; Al-Batran, S.-E. steht unter einer Creative Commons Namensnennung 3.0 Deutschland

Zitieren von Dokumenten: Bitte verwenden Sie für Zitate nicht die URL in der Adresszeile Ihres Webbrowsers, sondern entweder die angegebene DOI, URN oder die persistente URL, deren langfristige Verfügbarkeit wir garantieren. [mehr ...]

Abstract

Background: Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between tumor cell, T cell and accessory cells. Methods: Patients (pts) with Her2/neu (1+/SISH positive, 2+ and 3+) expressing tumors progressing after standard therapy were treated to investigate safety, tolerability and preliminary efficacy. In this study, ertu was applied i.v. in 2 cycles following a predefined dose escalating scheme. Each cycle consisted of five ascending doses (10–500 μg) applied weekly within 28 days with a 21 day treatment-free interval. If 2 pts experienced a dose limiting toxicity (DLT) at a given dose level, the maximum tolerated dose (MTD) had been exceeded. Results: Fourteen heavily pretreated pts (e.g. breast, rectal, gastric cancer) were enrolled in the four main cohorts. Three (21 %) pts had to be replaced. Two serious adverse events (SAE) with possible relation to the investigational drug were seen, both fully reversible. A DLT was not detected. Consequently, the MTD could not be determined. All adverse events (AE) were transient and completely reversible. Most frequent AEs were fatigue (14/14), pain (13/14), cephalgia (12/14), chills (11/14), nausea (8/14), fever (7/14), emesis (7/14) and diarrhea (5/14). Single doses up to 300 μg were well tolerated (total dose up to 800 μg per cycle). We observed one partial remission and two disease stabilizations after first treatment cycle. Conclusions: Single doses up to 300 μg could be safely administered in an escalating dose scheme. Immunological responses and clinical activity warrant further evaluation in patients with Her2 over expressing tumors. Trial registration EudraCT number: 2011-003201-14; ClinicalTrials.gov identifier: NCT01569412

Dokumententyp: Artikel
Titel der Zeitschrift: BMC Cancer
Band: 16
Nummer: 420
Verlag: BioMed Central; Springer
Ort der Veröffentlichung: London; Berlin; Heidelberg
Erstellungsdatum: 20 Jul. 2016 10:53
Erscheinungsjahr: 2016
ISSN: 1471-2407
Seitenbereich: S. 1-10
Institute/Einrichtungen: Medizinische Fakultät Heidelberg und Uniklinikum > Universitäts-Frauenklinik
DDC-Sachgruppe: 610 Medizin
Leitlinien | Häufige Fragen | Kontakt | Impressum |
OA-LogoDINI-Zertifikat 2013Logo der Open-Archives-Initiative